Discover promising gene therapy results from Tenaya Therapeutics, Inc.'s TN-201 and TN-401 projects, potential impact on ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will ...

Bryan Johnson, who’s spending hundreds of millions of dollars on treatments designed to extend his life, is many things to ...

Cardiac bridging integrator 1 gene therapy rescues chronic non-ischemic heart failure in minipigs. npj Regenerative Medicine , 2024; 9 (1) DOI: 10.1038/s41536-024-00380-0 Cite This Page : ...

Heart failure has historically been irreversible, but the outcome of a new study suggests that could someday change. At the University of Utah, scientists used a new gene therapy that was shown to ...

Researchers have successfully repaired damaged mouse hearts using a protein from zebrafish. They discovered that the protein Hmga1 plays a key role in heart regeneration in zebrafish. In mice, this ...

The global gene therapy market is expected to be worth USD 8.98 billion in 2024 and USD 57.13 billion by 2034, growing at a CAGR of 18.52% between the two years.Luton, Bedfordshire, United Kingdom, ...

Previous attempted therapies for heart failure have shown improvements to heart function on the order of 5-10%. cBIN1 gene therapy improved function by 30%. "It's night and day," Shaw adds.

New research shows the gene therapy didn't just prevent heart failure from worsening in four lab pigs, but actually prompted hearts to repair and grow stronger. Advertisement "Even though the ...

Their study showed that the adeno-associated virus 9 (AAV9)-packaged cardiac bridging integrator 1 (cBIN1) gene therapy increased the amount of blood the heart can pump and dramatically improved ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...